April 26th 2024
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Accepts BLA for Ublituxumab and Umbralisib for Chronic Lymphocytic Leukemia
May 25th 2021The FDA has accepted the biologic license application (BLA) for ublituximab in combination with umbralisib for the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Real-World Study Shows Limited Implementation of Recommended Biomarker Testing in CLL
May 4th 2021In an interview with Targeted Oncology, Mato, a hematologic oncologists and the director of the CLL Program at Memorial Sloan Kettering Cancer Center, discussed biomarker testing in CLL, and the future of BTK inhibitors in the CLL paradigm.
Read More
Prior Comorbidities Predict Risk of Treatment-Emergent Atrial Fibrillation in CLL
May 3rd 2021Roughly 4% of patients with chronic lymphocytic leukemia treated with ibrutinib may experience atrial fibrillation, but their comorbidities, rather than their CLL-related factors, predict risk of treatment-emergent AF.
Read More
Zanubrutinib Shown Noninferior to Ibrutinib for Patients With R/R CLL/SLL
April 29th 2021The use of zanubrutinib was found to be noninferior to treatment with ibrutinib for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, meeting the primary end point of the phase 3 ALPINE trial.
Read More
Ibrutinib Extends PFS in Patients with TP53-Mutated Chronic Lymphocytic Leukemia
March 30th 2021In an interview with Targeted Oncology, John N. Allan, MD, a hematology oncologist at Weill Cornell Medicine, discussed how ibrutinib extends PFS in patients with CLL. He also discussed combination therapy in the future of CLL treatment.
Read More
Rolling BLA for Ublituximab and Umbralisib in CLL Completed for FDA Submission
March 29th 2021The rolling submission of a Biologics License Application for the combination of ublituximab and umbralisib for the treatment of chronic lymphocytic leukemia has been completed for submission to the FDA.
Read More
Clinical Benefit Demonstrated With Ublituximab Plus Ibrutinib in R/R CLL
March 15th 2021Patients with relapsed or refractory high-risk chronic lymphocytic leukemia achieved a statistically higher rate of overall response when the glycoengineered, type I anti-CD20 monoclonal antibody ublituximab was added to the Bruton’s tyrosine kinase inhibitor ibrutinib, according to results from the phase 3 GENUINE study.
Read More
Ublituximab Added to Ibrutinib Demonstrates ORR Benefit for Relapsed/Refractory CLL
March 9th 2021The phase 3 GENUINE study demonstrated a response benefit with the addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib for patients with relapsed or refractory high-risk chronic lymphocytic leukemia.
Read More
Evidence Supports BTK Inhibition in Chronic Lymphocytic Leukemia
January 28th 2021The role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia is supported by clinical trial research. During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Peter Hillmen, MB ChB, PhD, provided evidence around acalabrutinib for the case of a 61-year-old woman.
Read More
Progression-Free Survival With Acalabrutinib Non-Inferior to Ibrutinib in High-Risk CLL
January 26th 2021In adults with previously treated, high-risk chronic lymphocytic leukemia, treatment with acalabrutinib was found to be non-inferior to treatment with ibrutinib in terms of progression-free survival, meeting the primary end point of the phase 3 ELEVATE-RR clinical trial.
Read More
Details of Different Therapies and Modalities Decide Treatment of CLL in the Second Line
January 13th 2021For the second-line treatment of patients with chronic lymphocytic leukemia, the armamentarium includes many therapies and strategies. Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute, discussed how to select treatment for patients during a Targeted Oncology Case-Based Peer Perspectives event.
Read More
Ibrutinib-Based 1L Therapy Sustains Efficacy, Safety in TP53+ Chronic Lymphocytic Leukemia
January 12th 2021The sustainability of efficacy and safety with frontline ibrutinib-based therapy used to treat patients with chronic lymphocytic leukemia who have TP53 aberrations was demonstrated, according to 4-year follow-up result of a pooled analysis.
Read More
Venetoclax Makes Inroads Into More Hematologic Setting
December 30th 2020Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention in 2020 for positive reports from phase 3 clinical trials exploring its use in acute myeloid leukemia and multiple myeloma.
Read More
Expert Expands on Treatment Choices in Patients With Genomic Aberrations in CLL
December 30th 2020During a Targeted Oncology Case-Based Peer Perspective event, Jonathon B. Cohen, MD, MS, discussed therapeutic options for a 71-year-old patients with chronic lymphocytic leukemia and a genomic aberration.
Read More
FDA Approves New Rituximab Biosimilar in NHL, CLL, and Other Hematologic Malignancies
December 18th 2020The FDA granted approval to rituximab-arrx, a biosimilar to rituximab as treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
Read More